Market capitalization | CHF27.53b |
Enterprise Value | CHF29.42b |
P/E (TTM) P/E ratio | 144.88 |
EV/FCF (TTM) EV/FCF | 168.17 |
EV/Sales (TTM) EV/Sales | 8.07 |
P/S ratio (TTM) P/S ratio | 7.55 |
P/B ratio (TTM) P/B ratio | 4.30 |
Dividend yield | 0.13% |
Last dividend (FY25) | CHF0.15 |
As a Free StocksGuide user, you can view scores for all 6,824 stocks worldwide.
13 Analysts have issued a Galderma forecast:
13 Analysts have issued a Galderma forecast:
Dec '24 |
+/-
%
|
||
Revenue | 3,647 3,647 |
-
|
|
Gross Profit | 2,534 2,534 |
-
|
|
EBITDA | 795 795 |
-
|
EBIT (Operating Income) EBIT | 554 554 |
-
|
Net Profit | 190 190 |
-
|
In millions CHF.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Galderma Group AG engages in the provision of science-based premium dermatology solutions. The firm is also involved in delivering a synergistic portfolio of flagship brands spanning the full spectrum of the fast-growing self-care dermatology market. The company was founded in 1981 and is headquartered in Zug, Switzerland.
Head office | Switzerland |
CEO | Flemming Ørnskov |
Website | www.galderma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.